{"id":"combigan-two-times-daily-bid","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Ocular hyperemia"},{"rate":"5-10","effect":"Eye irritation/discomfort"},{"rate":"5-10","effect":"Blurred vision"},{"rate":"5","effect":"Allergic conjunctivitis"},{"rate":"5","effect":"Dry eye"},{"rate":"5-10","effect":"Headache"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL211543","moleculeType":"Small molecule","molecularWeight":"497.60"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Brimonidine tartrate (alpha-2 agonist) stimulates alpha-2 adrenergic receptors to reduce aqueous humor production and enhance uveoscleral outflow. Timolol maleate (non-selective beta-blocker) decreases aqueous humor secretion by inhibiting beta-adrenergic receptors on the ciliary body. The combination provides additive IOP-lowering effects.","oneSentence":"Combigan combines a beta-adrenergic antagonist and an alpha-2 adrenergic agonist to reduce intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:30:31.999Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT06078592","phase":"PHASE4","title":"Comparison of Efficacy and Ocular Surface Assessment Between BRIDIN-plus and Combigan in Glaucoma or Ocular Hypertensive","status":"COMPLETED","sponsor":"CHA University","startDate":"2021-10-08","conditions":"Glaucoma, Ocular Hypertensive","enrollment":60},{"nctId":"NCT03235232","phase":"PHASE3","title":"BREMEN Eye Drops Versus Combigan for Open-angle Glaucoma or Intraocular Hypertension","status":"COMPLETED","sponsor":"EMS","startDate":"2021-02-01","conditions":"Ocular Hypertension, Primary Open-angle Glaucoma","enrollment":406},{"nctId":"NCT02623023","phase":"NA","title":"Prophylaxis for Anti-VEGF-induced IOP Elevation","status":"WITHDRAWN","sponsor":"McMaster University","startDate":"2019-01-01","conditions":"Ocular Hypertension","enrollment":""},{"nctId":"NCT04296916","phase":"NA","title":"Effect of Lowering IOP in Glaucoma Suspects With HM","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-04-17","conditions":"Glaucoma, Suspect, High Myopia","enrollment":264},{"nctId":"NCT00981786","phase":"PHASE4","title":"24-Hour Intraocular Pressure With Brinzolamide/Timolol Versus Brimonidine/Timolol","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2009-08","conditions":"Glaucoma","enrollment":51},{"nctId":"NCT02167035","phase":"PHASE4","title":"Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)","status":"COMPLETED","sponsor":"Cornerstone Health Care, PA","startDate":"2014-08","conditions":"Glaucoma, Ocular Hypertension","enrollment":43},{"nctId":"NCT02863705","phase":"PHASE4","title":"Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG)","status":"COMPLETED","sponsor":"Allergan","startDate":"2016-07-05","conditions":"Glaucoma, Open-Angle, Normal Tension Glaucoma","enrollment":118},{"nctId":"NCT02718547","phase":"NA","title":"The Relationship Between Intraocular Pressure and Macular Edema in Patients With Diabetic Macular Edema","status":"UNKNOWN","sponsor":"Meir Medical Center","startDate":"2017-03-26","conditions":"Complications of Diabetes Mellitus","enrollment":25},{"nctId":"NCT01217606","phase":"PHASE3","title":"Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-01","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":185},{"nctId":"NCT01518244","phase":"PHASE4","title":"Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-12","conditions":"Glaucoma","enrollment":50},{"nctId":"NCT00706927","phase":"NA","title":"Effect of Xalacom® (Latanoprost/Timolol) and Combigan® (Brimonidine/Timolol) Fixed Combination on Intraocular Pressure and Ocular Blood Flow in Patients With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2006-01","conditions":"Retina, Ocular Physiology","enrollment":16},{"nctId":"NCT01241240","phase":"PHASE3","title":"Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-03","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":192},{"nctId":"NCT01415401","phase":"PHASE4","title":"Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in Canada","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-09","conditions":"Glaucoma, Ocular Hypertension, Open-angle Glaucoma","enrollment":57},{"nctId":"NCT01514734","phase":"PHASE4","title":"Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Brazil","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2012-03","conditions":"Glaucoma","enrollment":9},{"nctId":"NCT00800540","phase":"PHASE4","title":"Circadian Ocular Perfusion Pressure and Ocular Blood Flow","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2009-02","conditions":"Glaucoma","enrollment":35},{"nctId":"NCT01229462","phase":"NA","title":"Safety and Efficacy of Brimonidine Tartrate/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-10","conditions":"Glaucoma, Ocular Hypertension","enrollment":238},{"nctId":"NCT01446497","phase":"PHASE4","title":"Efficacy and Safety Study of Combigan and 0.5% Timoptic in Normal Tension Glaucoma","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2010-10","conditions":"Normal Tension Glaucoma","enrollment":22},{"nctId":"NCT00651612","phase":"PHASE3","title":"Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients","status":"COMPLETED","sponsor":"Allergan","startDate":"2005-11","conditions":"Glaucoma, Ocular Hypertension","enrollment":604},{"nctId":"NCT00652106","phase":"PHASE3","title":"Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2003-06","conditions":"Glaucoma, Ocular Hypertension","enrollment":432}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Combigan Two Times Daily (BID)","genericName":"Combigan Two Times Daily (BID)","companyName":"Cornerstone Health Care, PA","companyId":"cornerstone-health-care-pa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Combigan combines a beta-adrenergic antagonist and an alpha-2 adrenergic agonist to reduce intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow. Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}